CymaBay Therapeutics to Participate in Upcoming Investor Conferences in October

NEWARK, Calif., Sept. 24, 2018 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. CBAY, a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that management will participate in upcoming investor conferences, including the 2018 Cantor Global Healthcare Conference, the LEERINK Partners Roundtable Series: Rare Disease & Oncology, and the ROTH Battle of the NASH Thrones Investor Conference.

2018 Cantor Global Healthcare Conference 
Date:Monday, October 1
Time:8:55am Eastern Time
Location:Intercontinental Barclay New York Hotel
Webcast:http://ir.cymabay.com/events
  
LEERINK Partners Roundtable Series:  Rare Disease & Oncology

Date:Tuesday, October 2
Time:8:30am Eastern Time
Location:Lotte New York Palace Hotel
Webcast:http://ir.cymabay.com/events
  
ROTH Battle of the NASH Thrones Investor Conference

Date:Wednesday, October 17
Time:Panel discussions and 1-on-1 meetings
Location:Park Hyatt New York Hotel

About CymaBay

CymaBay Therapeutics, Inc. (CBAY) is a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need. Seladelpar is a potent, selective, orally active PPARδ agonist, currently in development for the treatment of patients with primary biliary cholangitis (PBC), an autoimmune liver disease, and with non-alcoholic steatohepatitis (NASH).

For additional information about CymaBay visit www.cymabay.com.

Contact:              

Hans Vitzthum

LifeSci Advisors, LLC

212-915-2568

Hans@LifeSciAdvisors.com

CBAY Logo.jpg

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsPress Releases
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!